POMP AND PRESTIGE

Houston university declared No. 7 in the nation and best in Texas by new study

Rice University joins prestigious schools such as MIT and Harvard. Photo courtesy of Rice University

The Owls of Rice University have a lot to hoot about. The Houston school has been ranked as the seventh best college in the U.S. and the best college in Texas.

Niche.com's latest college rankings, released August 21, rely on U.S. Department of Education data coupled with reviews from current students, alumni, and parents to judge American colleges on 12 factors, including academics, campus, dorm life, and professors. Niche.com helps parents and students choose colleges and K-12 schools.

Last year's Niche.com list of the best colleges put Rice at No. 10, so it jumped up three spots this year.

On the new list, Rice ranks fourth among the colleges with the best professors, 10th among the colleges with the best value, and 16th among the hardest colleges to get into.

Here's Niche.com's new report card for the country's 10 best colleges:

  1. Massachusetts Institute of Technology, Boston
  2. Harvard University, Cambridge, Massachusetts
  3. Stanford University, Palo Alto, California
  4. Yale University, New Haven, Connecticut
  5. Duke University, Durham, North Carolina
  6. Princeton University, Princeton, New Jersey
  7. Rice University
  8. California Institute of Technology, Pasadena, California
  9. Brown University, Providence, Rhode Island
  10. University of Pennsylvania, Philadelphia

Known as the "Harvard of the South," Rice "is a premier research institution with a 300-acre campus that serves as a green oasis in the heart of Houston," Forbes noted in 2019.

In Niche.com's ranking this year, Rice earns bragging rights as the best college in Texas. Here are the state's top 10, according to Niche.com:

  1. Rice University
  2. University of Texas at Austin
  3. Texas A&M University, College Station
  4. Southern Methodist University, Dallas
  5. Trinity University, San Antonio
  6. Texas Christian University, Fort Worth
  7. Baylor University, Waco
  8. LeTourneau University, Longview
  9. Texas Tech University, Lubbock
  10. University of Texas at Dallas

Shortly after the Niche.com rankings came out, Rice appeared at the top of The Princeton Review's list of American colleges and universities with the overall best quality of life. Every year, The Princeton Review rates colleges and universities based on critiques submitted by students at 386 schools.

------

This article originally appeared on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News